Regeneron Pharmaceuticals 8-K

Summary

One-time 10-year performance-share awards for Regeneron’s CEO and chief scientific officer, plus equity stakes in a new subsidiary. The awards replace their annual equity awards through 2036 and tie potential payouts mainly to new-product revenue, with additional pipeline and shareholder-return measures.

Key Figures

• 2026 PSUs: maximum earnout of 2.7M for the CEO and 2.9M for the chief scientific officer. Revenue-based earnout starts at $10B in new-product annual revenue; $18B corresponds to 900,000 PSUs and $30B to 1.8M PSUs. Activity-based earnout is capped at 100,000 PSUs for the CEO and 300,000 for the chief scientific officer when revenue is below $10B.
• Revenue is measured for FY2032–FY2035. The maximum award caps may also be reached with $40B of new-product annual revenue in FY2034 or FY2035, provided Regeneron’s absolute total shareholder return is positive and exceeds the NASDAQ Biotechnology Total Return Index over the performance period. A relative-return modifier can adjust earned PSUs by ±20%.
• Any shares delivered before the end of 2035 are subject to a 20% holdback for the relative-return adjustment and generally cannot be sold until February 2036. The executives receive no additional equity awards under the plan until 2036; voluntary departure or retirement results in forfeiture of unvested PSUs.
• Schleifer and Yancopoulos each received an equity stake, partly subject to vesting, in a newly formed, majority-owned subsidiary exploring a potential non-core opportunity. It has nominal value, no significant assets and has not started operations.

Investor Takeaways

• FY2032–FY2035 new-product annual revenue and pipeline progress will determine PSU earnout; watch whether revenue reaches the $10B starting threshold and the higher payout levels.
• The subsidiary’s development and whether it proceeds with the potential opportunity remain uncertain.